Cingulate Inc. Issued Patent for Precision Timed Release Drug Technology


By Will Crow


Cingulate Inc. has received a patent issued from the United States Patent and Trademark Office for its buspirone tablet formulation incorporating its proprietary precision timed release technology. Photo credit: Shutterstock (Stock story).


Posted November 19, 2026

Kansas City, Kansas-based Cingulate Inc. announced that the United States Patent and Trademark Office has issued a patent for its precision timed-release drug.

The USPTO issued the U.S. Patent No. 12,797,335, titled “Trimodal, Precision-Timed Release Tablet, ” according to the release. The patent was issued on November 17.

The patent focuses on the Company’s development of CTx-2103, a once-daily, modified-release tablet that delivers three precisely timed doses of buspirone. Buspirone is an FDA-approved treatment for anxiety disorders.

“Cingulate remains focused on advancing CTx-1301, our lead ADHD treatment candidate, toward NDA resubmission and commercialization in the second half of 2027, if approved. We believe CTx-2103 represents an attractive opportunity to build a pipeline of assets beyond ADHD with our proprietary PTR™ Platform. The issuance of this patent further strengthens the Company’s intellectual property portfolio. Following approval of CTx-1301, Cingulate anticipates initiating the development of CTx-2103,” said Cingulate Chairman and CEO Shane J. Schaffer.

Cingulate’s other drug, CTx-1301, is a precision time-released technology allowing for a once-daily dose as opposed to other multi-dose ADHD medications and is currently seeking approval from the FDA.

In June, the FDA issued a complete response letter for the CTx-1301 NDA; Cingulate plans to resubmit the NDA between December 2026 and January 2026, according to the release.

In February, Cingulate closed a $12 million private investment deal and added former Kansas City-area entrepreneur Jeff Hargroves to its board of directors.